Program
spinosad
Also written as “Spinosad”, “APT-001 topical ophthalmic ointment (spinosad)” and “DE-105 ophthalmic solution”.
Its studies are mostly in Blepharitis · Lice Infestations · Epilepsy, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ParaPRO | 40 open or running | phase 4since Aug 6, 2012 | Oct 15, 2007 | none ahead |
| Aperta Biosciences | 21 open or running | phase 2since Dec 3, 2024 | Dec 3, 2024 | Jan 2027phase 2 · NCT07904767 |
| Santen Pharmaceutical | 10 open or running | phase 2since Sep 30, 2009 | Sep 30, 2009 | none ahead |
| Takeda | 10 open or running | phase 1since Jul 9, 2015 | Jul 9, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 15, 2007First studies: 2 phase 3 studiesNew to ParaPROParaPRO · NCT00545753, NCT00545168
- Dec 28, 2007Phase 1 study in Head LiceParaPRO · NCT00591331 · 37 enrolled · United States
- Sep 30, 2009Santen Pharmaceutical's first study: phase 2 study in Persistent Corneal Epithelial DefectNew to Santen PharmaceuticalSanten Pharmaceutical · NCT00988494 · 45 enrolled · Japan
- Aug 6, 2012Phase 4 study in Lice InfestationsParaPRO · NCT01660321 · 26 enrolled · United States
- Jul 9, 2015Takeda's first study: phase 1 study in EpilepsyNew to TakedaTakeda · NCT02497235 · 11 enrolled · United States
- Dec 3, 2024Aperta Biosciences's first study: phase 2 study in BlepharitisNew to Aperta BiosciencesAperta Biosciences · NCT06720896 · 66 enrolled · Guatemala
- Oct 23, 2026Phase 2 study in BlepharitisAperta Biosciences · NCT07904767 · 15 planned · Guatemala
Ahead
- Jan 2027Primary completion: phase 2 study in BlepharitisAperta Biosciences · NCT07904767
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Nicotinic acetylcholine receptor agonist”ChEMBL 37, by rule
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07904767Blepharitis · Guatemala | 2 | Not yet recruiting | Aperta Biosciences | Jan 2027 | 15 |
| NCT06720896Blepharitis · Guatemala | 2 | Completed | Aperta Biosciences | Jul 13, 2026 | 66 |
| NCT02497235Epilepsy · United States | 1 | Completed | Takeda | Dec 2015 | 11 |
| NCT01660321Lice Infestations · United States | 4 | Completed | ParaPRO | Oct 2011 | 26 |
| NCT00988494Persistent Corneal Epithelial Defect · Japan | 2 | Completed | Santen Pharmaceutical | 45 | |
| NCT00591331Head Lice · United States | 1 | Completed | ParaPRO | Dec 2007 | 37 |
| NCT00545753Lice Infestations · United States | 3 | Completed | ParaPRO | Mar 2008 | 558 |
| NCT00545168Pediculus Capitis Infestation · United States | 3 | Completed | ParaPRO | Mar 2008 | 480 |
How it is read
Names in the registry
- “Spinosad”, 4 entries
- “APT-001 topical ophthalmic ointment (spinosad)”, 2 entries
- “DE-105 ophthalmic solution”, 2 entries
- “[18F]MNI-792 (tracer)”, 1 entry
- “spinosad”, 1 entry
Conditions, from the studies’ own filings
- Blepharitis, 2 studies
- Lice Infestations, 2 studies
- Epilepsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.